Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ARTC's Cash to Debt is ranked higher than
79% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. ARTC: No Debt )
ARTC' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: No Debt

Equity to Asset 0.68
ARTC's Equity to Asset is ranked higher than
71% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ARTC: 0.68 )
ARTC' s 10-Year Equity to Asset Range
Min: 0.58   Max: 0.94
Current: 0.68

0.58
0.94
Interest Coverage 16.19
ARTC's Interest Coverage is ranked higher than
55% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. ARTC: 16.19 )
ARTC' s 10-Year Interest Coverage Range
Min: 0.01   Max: 9999.99
Current: 16.19

0.01
9999.99
F-Score: 5
Z-Score: 6.73
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.46
ARTC's Operating margin (%) is ranked higher than
76% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. ARTC: 8.46 )
ARTC' s 10-Year Operating margin (%) Range
Min: -153.33   Max: 17.41
Current: 8.46

-153.33
17.41
Net-margin (%) 6.89
ARTC's Net-margin (%) is ranked higher than
78% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. ARTC: 6.89 )
ARTC' s 10-Year Net-margin (%) Range
Min: -128.33   Max: 17.07
Current: 6.89

-128.33
17.07
ROE (%) 6.46
ARTC's ROE (%) is ranked higher than
73% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. ARTC: 6.46 )
ARTC' s 10-Year ROE (%) Range
Min: -32.77   Max: 12.74
Current: 6.46

-32.77
12.74
ROA (%) 4.39
ARTC's ROA (%) is ranked higher than
75% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ARTC: 4.39 )
ARTC' s 10-Year ROA (%) Range
Min: -28.84   Max: 8.92
Current: 4.39

-28.84
8.92
ROC (Joel Greenblatt) (%) 38.16
ARTC's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. ARTC: 38.16 )
ARTC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -67.65   Max: 64.52
Current: 38.16

-67.65
64.52
Revenue Growth (%) 0.10
ARTC's Revenue Growth (%) is ranked higher than
61% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ARTC: 0.10 )
ARTC' s 10-Year Revenue Growth (%) Range
Min: 0.1   Max: 87.4
Current: 0.1

0.1
87.4
EBITDA Growth (%) -15.80
ARTC's EBITDA Growth (%) is ranked higher than
63% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. ARTC: -15.80 )
ARTC' s 10-Year EBITDA Growth (%) Range
Min: -25.6   Max: 64.2
Current: -15.8

-25.6
64.2
EPS Growth (%) -14.70
ARTC's EPS Growth (%) is ranked higher than
64% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. ARTC: -14.70 )
ARTC' s 10-Year EPS Growth (%) Range
Min: -44.1   Max: 272.1
Current: -14.7

-44.1
272.1
» ARTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ARTC Guru Trades in Q1 2013

Joel Greenblatt 38,119 sh (+96.91%)
Paul Tudor Jones 127,600 sh (+27.6%)
Jim Simons 450,718 sh (+2.64%)
Mario Gabelli 336,600 sh (-4.59%)
Steven Cohen 1,126,846 sh (-26.77%)
» More
Q2 2013

ARTC Guru Trades in Q2 2013

Jim Simons 534,400 sh (+18.57%)
Paul Tudor Jones 128,600 sh (+0.78%)
Stanley Druckenmiller Sold Out
Mario Gabelli 334,600 sh (-0.59%)
Steven Cohen 748,772 sh (-33.55%)
Joel Greenblatt 19,466 sh (-48.93%)
» More
Q3 2013

ARTC Guru Trades in Q3 2013

Joel Greenblatt 98,823 sh (+407.67%)
Jim Simons 593,600 sh (+11.08%)
Mario Gabelli 334,000 sh (-0.18%)
Paul Tudor Jones 125,000 sh (-2.8%)
Steven Cohen 117,412 sh (-84.32%)
» More
Q4 2013

ARTC Guru Trades in Q4 2013

Steven Cohen 290,275 sh (+147.23%)
Paul Tudor Jones 186,395 sh (+49.12%)
Jim Simons 789,400 sh (+32.99%)
Joel Greenblatt Sold Out
Mario Gabelli 325,300 sh (-2.6%)
» More
» Details

Insider Trades

Latest Guru Trades with ARTC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.11%$34.49 - $40.03 $ 48.6331%0
Joel Greenblatt 2013-09-30 Add 407.67%0.09%$31.67 - $37.37 $ 48.6339%98823
Joel Greenblatt 2013-06-30 Reduce -48.93%0.03%$33.03 - $36.19 $ 48.6341%19466
Joel Greenblatt 2013-03-31 Add 96.91%0.03%$34.59 - $36.88 $ 48.6336%38119
Joel Greenblatt 2012-12-31 Reduce -47.09%0.04%$29.73 - $34.09 $ 48.6350%19359
Joel Greenblatt 2012-09-30 Reduce -50.25%0.08%$27.35 - $32.4 $ 48.6364%36588
George Soros 2012-09-30 Sold Out 0.02%$27.35 - $32.4 $ 48.6364%0
Joel Greenblatt 2012-03-31 Add 58.88%0.06%$24.74 - $32.52 $ 48.6384%72128
George Soros 2012-03-31 Reduce -31.46%0.03%$24.74 - $32.52 $ 48.6384%50000
Joel Greenblatt 2011-12-31 Add 24.38%0.03%$25.56 - $31.84 $ 48.6366%45398
Joel Greenblatt 2011-09-30 Add 101.04%0.09%$27.98 - $34.77 $ 48.6353%36498
George Soros 2011-09-30 Reduce -45.16%0.03%$27.98 - $34.77 $ 48.6353%77052
John Hussman 2011-06-30 Sold Out $32.31 - $35.33 $ 48.6345%0
John Hussman 2011-03-31 Reduce -51.18%0.27%$27.82 - $35.27 $ 48.6355%476000
Joel Greenblatt 2011-03-31 New Buy0.17%$27.82 - $35.27 $ 48.6355%16645
George Soros 2011-03-31 New Buy0.06%$27.82 - $35.27 $ 48.6355%141304
Mario Gabelli 2011-03-31 Reduce -35.82%0.06%$27.82 - $35.27 $ 48.6355%440000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 73.90
ARTC's P/E(ttm) is ranked lower than
62% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. ARTC: 73.90 )
ARTC' s 10-Year P/E(ttm) Range
Min: 22.25   Max: 525.63
Current: 73.9

22.25
525.63
P/B 3.40
ARTC's P/B is ranked higher than
56% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ARTC: 3.40 )
ARTC' s 10-Year P/B Range
Min: 0.37   Max: 5.45
Current: 3.4

0.37
5.45
P/S 3.70
ARTC's P/S is ranked lower than
61% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ARTC: 3.70 )
ARTC' s 10-Year P/S Range
Min: 0.28   Max: 5.89
Current: 3.7

0.28
5.89
PFCF 42.50
ARTC's PFCF is ranked lower than
55% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. ARTC: 42.50 )
ARTC' s 10-Year PFCF Range
Min: 5.59   Max: 895
Current: 42.5

5.59
895
EV-to-EBIT 45.50
ARTC's EV-to-EBIT is ranked lower than
63% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. ARTC: 45.50 )
ARTC' s 10-Year EV-to-EBIT Range
Min: 10   Max: 12832.2
Current: 45.5

10
12832.2
PEG 5.00
ARTC's PEG is ranked higher than
54% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. ARTC: 5.00 )
ARTC' s 10-Year PEG Range
Min: 1.93   Max: 5
Current: 5

1.93
5
Shiller P/E 927.10
ARTC's Shiller P/E is ranked lower than
70% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 26.95 vs. ARTC: 927.10 )
ARTC' s 10-Year Shiller P/E Range
Min: 59.45   Max: 990.6
Current: 927.1

59.45
990.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 57.90
ARTC's Price/Net Cash is ranked lower than
79% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 13.75 vs. ARTC: 57.90 )
ARTC' s 10-Year Price/Net Cash Range
Min: 6.87   Max: 153.13
Current: 57.9

6.87
153.13
Price/Net Current Asset Value 15.90
ARTC's Price/Net Current Asset Value is ranked lower than
61% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 8.80 vs. ARTC: 15.90 )
ARTC' s 10-Year Price/Net Current Asset Value Range
Min: 3.83   Max: 291.45
Current: 15.9

3.83
291.45
Price/Tangible Book 6.20
ARTC's Price/Tangible Book is ranked lower than
60% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ARTC: 6.20 )
ARTC' s 10-Year Price/Tangible Book Range
Min: 1.22   Max: 12.13
Current: 6.2

1.22
12.13
Price/DCF (Projected) 2.30
ARTC's Price/DCF (Projected) is ranked higher than
52% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ARTC: 2.30 )
ARTC' s 10-Year Price/DCF (Projected) Range
Min: 0.37   Max: 14.85
Current: 2.3

0.37
14.85
Price/Median PS Value 1.20
ARTC's Price/Median PS Value is ranked higher than
53% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ARTC: 1.20 )
ARTC' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 3.52
Current: 1.2

0.13
3.52
Price/Graham Number 3.80
ARTC's Price/Graham Number is ranked lower than
63% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ARTC: 3.80 )
ARTC' s 10-Year Price/Graham Number Range
Min: 1.92   Max: 38.44
Current: 3.8

1.92
38.44
Earnings Yield (Greenblatt) 2.20
ARTC's Earnings Yield (Greenblatt) is ranked lower than
54% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. ARTC: 2.20 )
ARTC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 10
Current: 2.2

0.1
10
Forward Rate of Return (Yacktman) 1.89
ARTC's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ARTC: 1.89 )
ARTC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1   Max: 27.6
Current: 1.89

-1
27.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BQK.Germany
ArthroCare was incorporated in California in 1993 and reincorporated in Delaware in 1995. The Company is a multi-business medical device Company that develops, manufactures and markets minimally invasive surgical products, many of which are based on its patented Coblation(r) technology. The Company has grown well beyond its roots in arthroscopy to capitalize on numerous market opportunities across several medical specialties, improving many existing soft-tissue surgical procedures and enabling new minimally invasive procedures. With its innovative technologies, the Company is improving the lives of individuals suffering from conditions as diverse as torn rotator cuffs and anterior cruciate ligaments to herniated discs and enlarged tonsils/tonsillitis. The Company currently markets minimally invasive surgical products across three core business units-ArthroCare Sports Medicine, which include shoulder and knee arthroscopic products; ArthroCare Spine, which include spinal and neurosurgery products; and ArthroCare Ear, Nose and Throat, which include ear, nose, throat and the Visage(r) cosmetic products; - but also has developed, manufactured and marketed Coblation-based and complementary products for application in neurology, cosmetic surgery, urology and gynecology, with research continuing in additional areas. In each of its core business units, the Company is focusing on driving the application of enabling technologies, primarily for plasma-based soft tissue removal, and increasing the number of minimally invasive procedures being performed. The Company is marketing and selling its arthroscopic/sports medicine, spinal surgery, ENT and cosmetic surgery products using a combination of distributors supported by regional sales mangers, a direct sales force and corporate partners to sell its products both domestically and internationally. The Company owns over 170 issued U.S. patents and over 195 issued international patents. The Company's products are considered medical devices and are subject to regulation in the United States, with the approval of FDA for each of its products. Its primary competitors include Medtronic, Inc., Smith & Nephew, Stryker Corporation, Johnson & Johnson, Olympus (through its subsidiary Gyrus) and Arthrex, Inc.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide